Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4301
Montauk Renewables
MNTK
$262M
| $183K | ﹤0.01% |
109,376
-138,280
| -56% | -$266K |
|
4302
SR Bancorp
SRBK
$147M
| $183K | ﹤0.01% |
11,601
+688
| +6% | +$10.6K |
|
4303
Nuvectis Pharma
NVCT
$632M
| $183K | ﹤0.01% |
24,185
+5,760
| +31% | +$37.5K |
|
4304
KULR Technology Group
KULR
$136M
| $182K | ﹤0.01% |
61,619
+10,377
| +20% | +$38.1K |
|
4305
SharkNinja
SN
$26.2B
| $182K | ﹤0.01% |
1,628
-45,978
| -97% | -$4.53M |
|
4306
Black Diamond Therapeutics
BDTX
$118M
| $182K | ﹤0.01% |
74,810
+51,942
| +227% | +$184K |
|
4307
PUT
Lionsgate Studios
LION
$3.46B
| $182K | ﹤0.01% |
+19,900
| New | +$142K |
|
4308
Sibanye-Stillwater
SBSW
$7.56B
| $181K | ﹤0.01% |
12,712
-156,496
| -92% | -$1.89M |
|
4309
FT Vest US Equity Moderate Buffer ETF September
GSEP
$345M
| $181K | ﹤0.01% |
+4,672
| New | +$179K |
|
4310
ProShares UltraShort Silver
ZSL
$57.1M
| $181K | ﹤0.01% |
+3,387
| New | +$372K |
|
4311
FT Vest US Equity Deep Buffer ETF May
DMAY
$380M
| $181K | ﹤0.01% |
3,997
-522
| -12% | -$23.3K |
|
4312
Global X S&P 500 Quality Dividend ETF
QDIV
$30.5M
| $180K | ﹤0.01% |
5,200
| – | – |
|
4313
CALL
Teladoc Health
TDOC
$1.2B
| $180K | ﹤0.01% |
25,700
| – | – |
|
4314
Maui Land & Pineapple Co
MLP
$322M
| $180K | ﹤0.01% |
10,616
+892
| +9% | +$14.4K |
|
4315
CVRx
CVRX
$68.7M
| $179K | ﹤0.01% |
25,262
+2,257
| +10% | +$20.6K |
|
4316
Medifast
MED
$131M
| $179K | ﹤0.01% |
16,769
+1,608
| +11% | +$19.2K |
|
4317
DHI Group
DHX
$174M
| $179K | ﹤0.01% |
115,266
+45,096
| +64% | +$85.3K |
|
4318
Envela
ELA
$418M
| $179K | ﹤0.01% |
13,353
+862
| +7% | +$9K |
|
4319
CALL
Vale
VALE
$61.7B
| $179K | ﹤0.01% |
13,700
| – | – |
|
|
NIU
4320
Niu Technologies
NIU
$163M
| $178K | ﹤0.01% |
58,846
| – | – |
|
|
ETHE
4321
Grayscale Ethereum Staking ETF Shares
ETHE
$1.53B
| $178K | ﹤0.01% |
+7,300
| New | +$207K |
|
|
EEX
4322
DELISTED
Emerald Holding
EEX
| $178K | ﹤0.01% |
39,724
+1,357
| +4% | +$5.84K |
|
4323
Eastern Company
EML
$155M
| $177K | ﹤0.01% |
9,002
+886
| +11% | +$18.1K |
|
4324
CALL
iShares MSCI Australia ETF
EWA
$1.46B
| $175K | ﹤0.01% |
+6,700
| New | +$177K |
|
4325
VanEck Video Gaming and eSports ETF
ESPO
$255M
| $175K | ﹤0.01% |
+1,685
| New | +$188K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.